Effect of Botulinum Toxin Type A on Motor Function in Children With Cerebral Palsy

Launched by INSTITUTO TELETÓN CHILE · Jun 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called botulinum toxin type A (often known as BoNT-A) affects the movement abilities and quality of life of children with a type of cerebral palsy called spastic hemiparesis. This condition causes muscle stiffness on one side of the body, which can make moving and daily activities harder. The study is led by experts at the Teletón Institute in Santiago and aims to see if giving BoNT-A injections can help improve how well children use their arms and legs and how they and their families feel about their daily lives.

Children and teens between 8 and 17 years old who have spastic hemiparesis cerebral palsy and are able to follow simple instructions may be eligible to join. Participants must be at a certain level of motor ability (classified as GMFCS I or II), and they should not have had a botulinum toxin injection in the past six months. If selected, they will receive carefully guided BoNT-A injections and will be checked before the treatment, then again at 4 weeks and 12 weeks afterward. These check-ups will look at their muscle function and overall well-being using different tests and questionnaires. The goal is to understand whether this treatment helps children move better and improves their quality of life in a safe and supportive way.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Spastic hemiparesis type Cerebral Palsy
• • Gross Motor Classification System I-II
• • Age 8 to 17 years (based on validation ages for scales to be used)
• • Minimum of 6 months since last botulinum toxin injection
• • Informed consent signed by legal guardian and assent from users aged 12 to 17 years
• Exclusion Criteria:
• • Cognitive impairment that prevents following instructions for functional assessments
• • Limitation of joint range not caused by spasticity
• • Patients diagnosed with other diseases causing spasticity, different from cerebral palsy
• • Patients with other neuromuscular diseases